FindTrial
Sign In

Atezolizumab 1200 mg in 20 ML Injection

DRUG8 trials

Sponsors

Rutgers, The State University of New Jersey, University of Michigan Rogel Cancer Center, Instituto Oncológico Dr Rosell, Fondazione Melanoma Onlus, Palleos Healthcare GmbH

Conditions

Early-stage Breast CancerExtensive-stage Small Cell Lung CancerLocally Advanced Solid TumorMelanomaMesotheliomas PleuralProstate CancerRefractory Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Phase 1

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
TerminatedNCT04081688
Rutgers, The State University of New JerseyRefractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Start: 2019-09-11End: 2024-04-30Updated: 2026-02-05
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
Active, not recruitingNCT04487756
Instituto Oncológico Dr RosellExtensive-stage Small Cell Lung Cancer
Start: 2021-03-17End: 2024-10-31Target: 20Updated: 2024-04-03
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
CompletedNCT04975958
Adlai Nortye Biopharma Co., Ltd.Locally Advanced Solid Tumor
Start: 2021-09-07End: 2025-01-24Updated: 2025-06-22

Phase 2

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
WithdrawnNCT04272645
University of Michigan Rogel Cancer CenterProstate Cancer
Start: 2020-10-31End: 2022-10-31Updated: 2020-07-15
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Active, not recruitingNCT04722575
Fondazione Melanoma OnlusMelanoma
Start: 2020-10-12End: 2027-06-30Updated: 2025-03-13
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
TerminatedNCT04770272
Palleos Healthcare GmbHTriple-negative Breast Cancer
Start: 2021-03-01End: 2024-10-02Updated: 2026-01-12
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
RecruitingNCT05332561
German Cancer Research CenterEarly-stage Breast Cancer
Start: 2023-06-29End: 2030-12-31Target: 240Updated: 2025-03-20

Phase 3

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
RecruitingNCT04996017
Gruppo Oncologico Italiano di Ricerca ClinicaMesotheliomas Pleural
Start: 2021-12-14End: 2029-06-30Target: 162Updated: 2025-03-13

Related Papers

Phase III study on atezolizumab versus placebo in adjuvant therapy of pleural mesothelioma patients after pleurectomy/decortication: Preliminary results of the AtezoMeso study.
Journal of Clinical Oncology2025-05-28
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.
Journal of Clinical Oncology2024-06-052 citations
A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC.
2024-05-161 citations
Abstract PO1-19-05: COGNITION/-GUIDE – Implementation of Precision Oncology in Early High-Risk Breast Cancer
Cancer Research2024-05-02
602 A phase I trial of atezolizumab and varlilumab in combination with radiation in patients with metastatic non-small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts2023-10-311 citations